PM
AQST icon

Penbrook Management’s Aquestive Therapeutics AQST Stock Holding History

Penbrook Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$106K Sell
25,565
-16,595
-39% -$67.4K 0.08% 90
2025
Q4 		$272K Sell
42,160
-1,425
-3% -$8.88K 0.19% 77
2025
Q3 		$244K Sell
43,585
-22,585
-34% -$97.7K 0.17% 85
2025
Q2 		$210K Buy
66,170
+43,585
+193% +$125K 0.08% 103
2025
Q1 		$65.5K Buy
+22,585
New +$68.4K 0.05% 105

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Penbrook Management's AQST Position: Q1 2026 in Review

Penbrook Management reduced its Aquestive Therapeutics (AQST) stake by 39% in Q1 2026, selling an estimated $67.4K and leaving 25,565 shares worth $106K. The position accounts for 0.08% of the portfolio, ranked #90.

Penbrook Management first reported a position in AQST in Q1 2025 and has held it in 5 quarters since. The position peaked at $272K in Q4 2025. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • Penbrook Management held 25,565 shares of Aquestive Therapeutics worth $106K as of Q1 2026.
  • Penbrook Management sold 16,595 Aquestive Therapeutics shares in Q1 2026, an estimated $67.4K.
  • Aquestive Therapeutics made up 0.08% of Penbrook Management's portfolio in Q1 2026, its #90 holding.
  • Penbrook Management first reported a position in Aquestive Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Penbrook Management's Aquestive Therapeutics position peaked at $272K in Q4 2025.
  • 179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Penbrook Management's 13F filing for Q1 2026, filed 21 Apr 2026.